top of page
Imagine diagnosing the cause of any infection in just six hours and targeting the exact pathogen.
Natantis makes this a reality.
Infections result in 13.66 million deaths each year- equating to three lives lost every second. While 65% of these infections are caused by bacteria, viruses, fungi, and parasites also contribute significantly.
Antimicrobial resistance (AMR) develops when pathogens are not promptly identified, leading to delayed targeted treatment and increased reliance on broad-spectrum antibiotics, contributing to nearly 5 million deaths annually. With the WHO emphasizing the urgent need for rapid AMR diagnostics, Natantis, a Heriot-Watt University spin out, is responding to this challenge with its CNASafe platform and iSEP-SEQ workflow, which quickly identifies a wide range of pathogens and facilitates targeted treatments to combat AMR.
With £1.45 million (~$1.9 million) raised and support from 20 leading organizations—including the Global Sepsis Alliance, UK Sepsis Trust, Public Health Scotland, NHS Scotland, Oxford Nanopore Technologies—as well as a 100-patient NHS validation study set to begin in early 2025, Natantis is making significant strides in addressing this global health priority.
bottom of page